GCP
DMK

GSA Capital Partners’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

GSA Capital Partners’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,374
Closed -$250K – 1590
2020
Q4 		$250K Buy
7,374
+6,578
+826% +$293K 0.04% 847
2020
Q3 		$44K Buy
+796
New +$47.2K 0.01% 1191
2019
Q4 		– Sell
-399
Closed -$20K – 1804
2019
Q3 		$20K Sell
399
-1,595
-80% -$115K ﹤0.01% 1342
2019
Q2 		$181K Buy
+1,994
New +$243K 0.02% 1265

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's DMK Position: Q1 2021 in Review

GSA Capital Partners sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2021, closing a stake of 7,374 shares — an estimated $250K sold.

GSA Capital Partners first reported a position in DMK in Q2 2019 and held it in 4 quarters. The position peaked at $250K in Q4 2020. 53 funds tracked by Wall St. Rank hold DMK as of Q1 2021.

  • GSA Capital Partners reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2021 after selling out during the quarter.
  • GSA Capital Partners sold 7,374 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2021, an estimated $250K.
  • GSA Capital Partners first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2019 and held it in 4 quarters.
  • GSA Capital Partners's DMK Pharmaceuticals Corporation Common Stock position peaked at $250K in Q4 2020.
  • 53 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.